Liraglutide Improves Both Diabetic Nephropathy and Cardiomyopathy in the SDT Fatty Rat, a Cardiorenal Model of Type 2 Diabetes.

Key Word：
Glucagon-Like Peptide 1 (GLP-1) 、Liraglutide（リラグルチド）、Diabetic Nephropathy（糖尿病性腎症）、Cardiomyopathy（心筋症）、Heart failure with preserved ejection function (HFpEF) (収縮機能が保たれた心不全) 、Cardiorenal（心腎連関症候群）、obese, type 2 diabetic model（肥満、2型糖尿病モデル）

BRIAND PhD, F*¹, Shinohara, M², Kageyama, Y², Sulpice, T¹

¹PHYSIOGENEX, RESEARCH, ESCALQUENS, France, ²CLEA Japan Inc., Business Development, Tokyo, Japan

For more details, please click here (Google Search)

• ISN-WCN 2023: Queen Sirikit National Convention Center in Bangkok, Thailand.

• March 30 - April 2, 2023

Related CLEA Japan product: SDT fatty/Jcl

For the animal model, please click here ▼

 https://www.clea-japan.com/en/products/diabetes/item_a0150

 https://www.clea-japan.com/products/diabetes/item_a0150

Inquiry（お問い合わせ）

If you have any questions, please feel free to contact us.